---
title: "Alterity Therapeutics (ASX:ATH): CEO on FDA Phase 3, ATH434 & the Breakthrough MSA Treatment"
description: "Can Alterity Therapeutics (ASX:ATH) become one of the first companies to deliver a disease-modifying treatment for Multiple System Atrophy (MSA)? In this exclusive Homodeus Research webinar, Dr David Stamler, Managing Director & CEO of Alterity Therapeutics, discusses the latest progress of ATH434, the company's lead drug candidate targeting neurodegenerative diseases associated with pathological iron accumulation. The discussion covers Alterity's agreement with the U.S. FDA on the design of its pivotal Phase 3 registration study, the recently granted U.S. composition-of-matter patent for ATH434, clinical trial results, biomarker data, regulatory strategy, commercial opportunity and the key milestones investors should watch over the coming 12–24 months. Whether you're an investor interested in biotechnology, neuroscience or ASX healthcare stocks, this interview provides a detailed overview of Alterity's science, regulatory progress and long-term growth potential. Key Topics - Alterity Therapeutics company overview - ATH434 mechanism of action - Multiple System Atrophy (MSA) explained - FDA agreement on the Phase 3 registrational study - Recent U.S. patent grant for ATH434 - Clinical trial and biomarker results - Parkinsonian disorders and neurodegenerative diseases - Commercial opportunity for disease-modifying therapies - Upcoming catalysts and milestones - Live investor Q&A About Homodeus Research Homodeus Research provides independent investor education through in-depth interviews with ASX-listed companies, helping investors better understand business models, industry trends and long-term investment opportunities. 🔔 Subscribe for more CEO interviews, biotechnology analysis and ASX company research. Disclaimer: This video is provided for educational purposes only and does not constitute financial advice. Always conduct your own research and seek advice from a licensed financial adviser before making investment decisions."
canonical_url: "https://homodeus.one/research/videos/8Dwwjx3QnRQ"
markdown_url: "https://homodeus.one/research/videos/8Dwwjx3QnRQ.md"
published_date: "2026-08-26T08:08:20+00:00"
modified_date: "2026-10-10T13:31:59.157Z"
thumbnail_url: "https://i1.ytimg.com/vi/8Dwwjx3QnRQ/hqdefault.jpg"
embed_url: "https://www.youtube.com/embed/8Dwwjx3QnRQ"
source_url: "https://www.youtube.com/watch?v=8Dwwjx3QnRQ"
access: "full"
source: "Homodeus Research"
---

# Alterity Therapeutics (ASX:ATH): CEO on FDA Phase 3, ATH434 & the Breakthrough MSA Treatment

Published 2026-08-26T08:08:20+00:00.

Can Alterity Therapeutics (ASX:ATH) become one of the first companies to deliver a disease-modifying treatment for Multiple System Atrophy (MSA)?
In this exclusive Homodeus Research webinar, Dr David Stamler, Managing Director & CEO of Alterity Therapeutics, discusses the latest progress of ATH434, the company's lead drug candidate targeting neurodegenerative diseases associated with pathological iron accumulation.
The discussion covers Alterity's agreement with the U.S. FDA on the design of its pivotal Phase 3 registration study, the recently granted U.S. composition-of-matter patent for ATH434, clinical trial results, biomarker data, regulatory strategy, commercial opportunity and the key milestones investors should watch over the coming 12–24 months.
Whether you're an investor interested in biotechnology, neuroscience or ASX healthcare stocks, this interview provides a detailed overview of Alterity's science, regulatory progress and long-term growth potential.
Key Topics
- Alterity Therapeutics company overview
- ATH434 mechanism of action
- Multiple System Atrophy (MSA) explained
- FDA agreement on the Phase 3 registrational study
- Recent U.S. patent grant for ATH434
- Clinical trial and biomarker results
- Parkinsonian disorders and neurodegenerative diseases
- Commercial opportunity for disease-modifying therapies
- Upcoming catalysts and milestones
- Live investor Q&A
About Homodeus Research
Homodeus Research provides independent investor education through in-depth interviews with ASX-listed companies, helping investors better understand business models, industry trends and long-term investment opportunities.
🔔 Subscribe for more CEO interviews, biotechnology analysis and ASX company research.
Disclaimer: This video is provided for educational purposes only and does not constitute financial advice. Always conduct your own research and seek advice from a licensed financial adviser before making investment decisions.

Watch: https://www.youtube.com/watch?v=8Dwwjx3QnRQ